EUVIMED · CrossrefJournal
EANM Innovation
ISSN 3051-2913 · Elsevier BV
Latest articles
Quantitative assessment of [99mTc]Tc-sestamibi SPECT/CT for renal mass characterisation: A scoping review of methodologies
SSTR2 receptor states and cellular metabolism modulate 177Lu-DOTATATE binding affinity
Preclinical comparison of radiobiological and radiosensitizing effects in peptide receptor radionuclide therapy and external beam radiotherapy
EANM recommendations for dosimetry in targeted radionuclide therapy with alpha-emitters
Joint EANM/SNMMI procedural guideline for paediatric bone hybrid imaging with 99mTc-labelled radiopharmaceuticals and [18F]fluoride
Bone SPECT/CT in suspected facet joint arthropathy and non-infectious postoperative spine conditions. Part 1: Systematic review and evidence map
Bone SPECT/CT in suspected facet joint arthropathy and non-infectious postoperative spine conditions. Part 2: Joint EANM/ESNR/EUROSPINE clinical practice consensus guideline
Welcome to EANM Innovation – A new journey begins
In numeris veritas: Quantitative techniques in dynamic LAFOV PET imaging in oncology – A systematic review of current evidence and future prospects
Advancing targeted radionuclide therapy in nuclear medicine – A future perspective
Impact of regularization in optimizing distance-encoding biomorphic-informational neural networks for small nuclear medicine datasets
Defining synergy of integrating radiotherapy and radioligand therapy: insights from ESTRO 2025
Corrigendum to “Impact of regularization in optimizing distance-encoding biomorphic-informational neural networks for small nuclear medicine datasets” [EANM Innovation Vol 1 Dec. 2025 100008]
In vivo voxel-wise positronium lifetime imaging of thyroid cancer using clinically routine I-124 PET/CT
Characterization of cardio-brain dysfunction in Parkinson's disease by PET imaging
Association between SSTR2 expression and [68Ga]Ga-DOTATOC PET/CT uptake in neuroblastoma: A retrospective analysis
Digital twins in computational medicine with a specific focus on nuclear oncology. Where do we stand?
EARL Theranostics Centre of Excellence certification: raising the standard of targeted radionuclide therapy care in Europe and beyond
SSTR-directed radiopharmaceutical therapy in a patient with small cell lung cancer: an intrapatient comparison of SSTR-agonist and antagonist
Environmental life cycle assessment of [18F]FDG PET/CT imaging in a hospital-based nuclear medicine department
Reactive bone marrow [18F]FDG uptake after G-CSF and anti-tumour therapy in neuroblastoma: guidance for PET scheduling
UNLOCKING ENZYME-POWERED RADIOFLUORINATION OF SINGLE-DOMAIN ANTIBODIES USING VYPAL2
DESIGN, SYNTHESIS AND EVALUATION OF A NOVEL FIBROBLAST ACTIVATION PROTEIN INHIBITOR (FAPI)-TRACER RADIOLABELED USING AN ULTRAFAST PHOTOCLICK REACTION
USE OF HIGHLY REACTIVE CLICK-TO-RELEASE COMPONENTS FOR IMPROVED CLICK-CLEAVABLE RADIOIMMUNOTHERAPY
OVERCOMING CETUXIMAB RESISTANCE IN COLORECTAL CANCER USING AN EGFR/SHP2-TARGETED THERANOSTIC ANTIBODY-DRUG CONJUGATE
HEXADENTATE ACYCLIC DACH-BASED CHELATORS FOR [212/203PB]PB2+: TOWARDS POTENTIAL APPLICATIONS IN NUCLEAR MEDICINE
DEVELOPMENT & PRECLINICAL EVALUATION OF [18F]ALF-/[213BI]BI-3P-C-NETA-FAP2286, A PERFECT MATCH FOR SHORT-LIVED PET IMAGING AND TAT.
PRECLINICAL EVALUATION OF A NEW THERANOSTIC PAIR FOR CAIX-POSITIVE TUMOURS: [18F]ALF-NOTA-DPI-4452 AND [161TB]TB-DOTA-DPI-4452
CARBOXYLIC- AND AMIDE DONOR-FUNCTIONALIZED PYRIDINE-N-TRANS-SUBSTITUTED CYCLEN-BASED CHELATORS FOR LEAD-203 AND LEAD-212 THERANOSTIC RADIOPHARMACEUTICALS
OVERCOMING CHELATOR LIMITATIONS IN THERANOSTICS: A NEW NOTA-DERIVED HYBRID FOR AL-18F AND 177LU
EUVIMED